Anthelcide EQ

Manufacturer
Zoetis Inc.
Effective date
2026-01-27
Label type
OTC ANIMAL DRUG LABEL
Version
3
Source
full-release
Hydrated at
2026-06-01 02:45:52

Label at a glance#

ProductAnthelcide EQ
Active ingredientOXIBENDAZOLE
Label structure12 sections

Dosage and administration

The dosage of oxibendazole is 10 mg/kg (2.2 lb) of body weight (15 mg/kg for strongyloides). Each mark on the syringe delivers Anthelcide EQ to treat 100 lb (67 lb for strongyloides). Horses maintained on premises where reinfection is likely to occur should be retreated in 6–8 weeks. Do not underdose. Ensure each animal receives a complete dose based on a current body weight. Underdosing may result in ineffective ...

Storage and handling

Store at controlled room temperature 15°–30°C (59°–86°F).

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

HORSE DEWORMER

For use in horses only

DESCRIPTION

DESCRIPTION SECTION

Anthelcide EQ Paste is a paste formulation of oxibendazole, a broad-spectrum benzimidazole anthelmintic. This formulation has been developed for ease of administration. Each syringe contains 0.85 oz (24 g) of paste.

 Anthelcide EQ Paste contains:
 Oxibendazole 22.7%

INDICATIONS

VETERINARY INDICATIONS SECTION

Anthelcide EQ Paste is indicated for removal and control of: large strongyles (Strongylus edentatus, S. equinus, S. vulgaris); small strongyles (species of the genera Cylicostephanus, Cylicocyclus, Cyathostomum, Triodontophorus, Cylicodontophorus, and Gyalocephalus); large roundworms (Parascaris equorum); pinworms (Oxyuris equi) including various larval stages; and threadworms (Strongyloides westeri).

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Anthelcide EQ is contraindicated in severely debilitated horses or horses suffering from infectious disease, toxemia, or colic.

Warning

WARNINGS SECTION

  Do not use in horses intended for human consumption.

PRECAUTIONS

PRECAUTIONS SECTION

Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

Keep Out of Reach of Children.

OTHER WARNINGS

WARNINGS SECTION

Parasite resistance may develop to any dewormer, and has been reported for most classes of dewormers. Treatment with a dewormer used in conjunction with parasite management practices appropriate to the geographic area and the animal(s) to be treated may slow the development of parasite resistance. Fecal examinations or other diagnostic tests and parasite management history should be used to determine if the product is appropriate for the herd prior to the use of any dewormer. Following the use of any dewormer, effectiveness of treatment should be monitored (for example, with the use of a fecal egg count reduction test or another appropriate method). A decrease in a drug’s effectiveness over time as calculated by fecal egg count reduction tests may indicate the development of resistance to the dewormer administered. Your parasite management plan should be adjusted accordingly based on regular monitoring.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The dosage of oxibendazole is 10 mg/kg (2.2 lb) of body weight (15 mg/kg for strongyloides). Each mark on the syringe delivers Anthelcide EQ to treat 100 lb (67 lb for strongyloides). Horses maintained on premises where reinfection is likely to occur should be retreated in 6–8 weeks.

Do not underdose. Ensure each animal receives a complete dose based on a current body weight. Underdosing may result in ineffective treatment, and encourage the development of parasite resistance.

Dosage Table
10 mg/kg 15 mg/kg
Syringe Mark Horse Weight (lb) Syringe Mark Horse Weight (lb)
 100 100 300 200
 200 200 600 400
 400 400 900 600
 600 600 1200 800
 800 800  
 1000 1000  
 1200 1200  

Anthelcide EQ is compatible with carbon disulfide, which can be used concurrently for bot control (Gasterophilus spp.) when administered by a veterinarian. Routine carbon disulfide cautions must be observed.

USE OF SYRINGE

SPL UNCLASSIFIED SECTION

Determine the weight of the horse and dial the correct setting on the plunger, having the side of the wheel nearest the barrel on the desired mark. Remove the cap from the syringe. Insert the tip of the syringe into the side of the animal's mouth between the incisor and molar teeth and press the plunger down as far as it will go, depositing the paste on the back of the tongue.

HOW SUPPLIED

HOW SUPPLIED SECTION

Anthelcide EQ paste is supplied in 0.85-oz (24-g) syringes.

STORAGE

STORAGE AND HANDLING SECTION

Store at controlled room temperature 15°–30°C (59°–86°F).

SPL UNCLASSIFIED SECTION

Approved by FDA under NADA # 121-042

zoetis

Distributed by:
Zoetis Inc.
Kalamazoo, MI 49007

52478000 
Revised: November 2025

PRINCIPAL DISPLAY PANEL - 24 g Syringe Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

24 g Syringe Label
24 g Syringe Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1009349ANTHELCIDE EQ 22.7 % Oral PastePSN3
1009345oxibendazole 22.7 % Oral PastePSN3
1009349oxibendazole 0.227 MG/MG Oral Paste [Anthelcide EQ]SBD3
1009345oxibendazole 0.227 MG/MG Oral PasteSCD3
1009349Anthelcide EQ 0.227 MG/MG Oral PasteSY3
1009349Anthelcide EQ 22.7 % Oral PasteSY3
1009345oxibendazole 22.7 % Oral PasteSY3

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
Data codeData Matrix40028069anthelcide-eq-1.jpg

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
54771-6045-2Anthelcide EQ24 g in 1 SYRINGEPASTE243

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 2 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
54771-604554771-6045-2

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 1 matching rows.

Name, UNII, Kind table
NameUNIIKind
OXIBENDAZOLE022N12KJ0XACTIB

Source Document#

Source XML

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.